VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

ALVAC-AI-H5 Influenza virus NS1 mutant vaccine PrV-HA (swine-origin H1N1) rSPV-HA1 (Swine influenza virus H1N1) Trovac-AI-H5
Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004747
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: ALVAC vaccine expressing the haemagglutinin of a highly pathogenic (HP) H5N1 avian influenza virus (AIV) (A/chicken/Indonesia/7/03) in pig(Kyriakis et al., 2009).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0002981
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse, pig, horse, macaque
  • NS1 from Influenza virus gene engineering:
  • Immunization Route: intranasal immunization
  • Vaccine Ontology ID: VO_0004698
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA gene engineering:
    • Type: Recombinant protein preparation
    • Description: Pseudorabies virus (PrV) strain Bartha (PrV-Ba) served as a vector for the expression of haemagglutinin (HA) of swine-origin H1N1 virus (Klingbeil et al., 2014).
    • Detailed Gene Information: Click Here.
  • Preparation: The pseudorabies virus (PrV) strain Bartha (PrV-Ba) was used as vector for the expression of haemagglutinin (HA) of swine-origin H1N1 virus (Klingbeil et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004636
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: Recombinant swinepox virus (rSPV-HA1) expressing hemagglutinin (HA1) of H1N1 SIV (Xu et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
  • Tradename: Trovac AI H5
  • Manufacturer: Merial
  • Vaccine Ontology ID: VO_0000839
  • Type: Recombinant vector vaccine
  • Status: Licensed
  • Host Species for Licensed Use: Pig
  • HA gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Preparation: Different vaccines expressing the haemagglutinin of a highly pathogenic (HP) H5N1 avian influenza virus (AIV) (A/chicken/Indonesia/7/03) (Kyriakis et al., 2009).
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Fowlpox virus-vectored H5 (Bublot et al., 2006)
Host Response Host Response Host Response Host Response Host Response

Mouse Response

Pig Response

  • Vaccination Protocol: Pigs were vaccinated twice, with a 4-week interval, with a canarypox (ALVAC) vector vaccine combined with an oil-in-water adjuvant, with the unadjuvanted NYVAC, or left unvaccinated (Kyriakis et al., 2009).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Six weeks after the second vaccination, all pigs were challenged intra-tracheally with low pathogenic (LP) H5N2 AIV A/chicken/Belgium/150/99 (Kyriakis et al., 2009).
  • Efficacy: The NYVAC and ALVAC adjuvanted vaccines consistently induced higher antibody titres than TROVAC or NYVAC without adjuvant. Following challenge, the H5N2 challenge virus was isolated from all unvaccinated pigs, while 19 out of 21 vaccinates showed complete virological protection (Kyriakis et al., 2009).

Pig Response

Pig Response

  • Vaccination Protocol: Piglets were infected intranasally with PrV-BaMI-synH1 as a live-virus vaccine, whereas control animals were immunized with PrV-Ba or not vaccinated (Klingbeil et al., 2014).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: A challenge with pandemic H1N1 SoIV A/California/7/09 performed 3 weeks after immunization (Klingbeil et al., 2014).
  • Efficacy: A single immunization of pigs with the PrV vector expressing the codon-optimized HA gene under control of P-MCMV induced high levels of HA-specific antibodies (Klingbeil et al., 2014).

Pig Response

  • Vaccination Protocol: At 5 weeks of age, groups 1 and 2 were individually inoculated intramuscularly in the neck area with rSPV-HA1 or wtSPV at 1 × 107.0 TCID50 in 1 ml EMEM per pig. Group 3 was inoculated with 1 ml EMEM (Xu et al., 2012).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: All pigs were challenged with 2 × 105.0 TCID50 H1N1 SIV per pig by nasal inoculation (Xu et al., 2012).
  • Efficacy: Complete protection of pigs against H1N1 SIV challenge was observed. No pigs showed evident systemic and local reactions to the vaccine and no SIV shedding was detected from pigs vaccinated with rSPV-HA1 after challenge (Xu et al., 2012).

Pig Response

  • Vaccination Protocol: Pigs were vaccinated twice, with a 4-week interval, with a fowlpox (TROVAC), a canarypox (ALVAC), or a vaccinia (NYVAC) vector vaccine combined with an oil-in-water adjuvant, with the unadjuvanted NYVAC, or left unvaccinated (Kyriakis et al., 2009).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Six weeks after the second vaccination, all pigs were challenged intra-tracheally with low pathogenic (LP) H5N2 AIV A/chicken/Belgium/150/99 (Kyriakis et al., 2009).
  • Efficacy: The NYVAC and ALVAC adjuvanted vaccines consistently induced higher antibody titres than TROVAC or NYVAC without adjuvant. Following challenge, the H5N2 challenge virus was isolated from all unvaccinated pigs, while 19 out of 21 vaccinates showed complete virological protection. Pox-vector vaccines were safe, immunogenic and efficacious against challenge with a heterologous H5 AIV, offering an alternative to classical inactivated vaccines (Kyriakis et al., 2009).

Horse Response

Macaque Response

References References References References References
Kyriakis et al., 2009: Kyriakis CS, De Vleeschauwer A, Barbé F, Bublot M, Van Reeth K. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine. 2009; 27(16); 2258-2264. [PubMed: 19428840].
Richt and García-Sastre, 2009: Richt JA, García-Sastre A. Attenuated influenza virus vaccines with modified NS1 proteins. Current topics in microbiology and immunology. 2009; 333; 177-195. [PubMed: 19768406].
Klingbeil et al., 2014: Klingbeil K, Lange E, Teifke JP, Mettenleiter TC, Fuchs W. Immunization of pigs with an attenuated pseudorabies virus recombinant expressing the haemagglutinin of pandemic swine origin H1N1 influenza A virus. The Journal of general virology. 2014; 95(Pt 4); 948-959. [PubMed: 24431235].
Xu et al., 2012: Xu J, Huang D, Liu S, Lin H, Zhu H, Liu B, Lu C. Immune responses and protective efficacy of a recombinant swinepox virus expressing HA1 against swine H1N1 influenza virus in mice and pigs. Vaccine. 2012; 30(20); 3119-3125. [PubMed: 22391400].
Bublot et al., 2006: Bublot M, Pritchard N, Swayne DE, Selleck P, Karaca K, Suarez DL, Audonnet JC, Mickle TR. Development and use of fowlpox vectored vaccines for avian influenza. Annals of the New York Academy of Sciences. 2006; 1081; 193-201. [PubMed: 17135511].
Kyriakis et al., 2009: Kyriakis CS, De Vleeschauwer A, Barbé F, Bublot M, Van Reeth K. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine. 2009; 27(16); 2258-2264. [PubMed: 19428840].